Hematology

ASCO pooled phase 3 data show that pirtobrutinib in treatment‑naive CLL/SLL delivers 93% responses, durable control, and low cardiac risk.

FACT-accredited centers vs nonaccredited centers may influence CAR T-cell therapy outcomes.

Six-year follow-up data from the SEQUOIA trial showed that zanubrutinib provided durable PFS and strong long-term outcomes in treatment-naïve CLL/SLL.

An overview of how earlier use of CAR T-cell therapy is reshaping multiple myeloma treatment and what pharmacists should know about toxicity management, supportive care, and evolving clinical practice.

Data from a phase 1/2 trial revealed that CRISPR–Cas9–edited donor stem cell transplants lacking CD33 enabled rapid engraftment and allowed posttransplant gemtuzumab ozogamicin maintenance in high-risk patients with AML/MDS without prolonged hematologic toxicity.

FDA approval brings the first all-oral AML combination therapy, decitabine/cedazuridine with venetoclax, for older or unfit patients, cutting clinic visits.

FDA approves sonrotoclax for patients who have received at least 2 lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.

Effective real-world management of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) is critical to safely delivering CAR T-cell therapies and bispecific antibodies.

The ACCESS trial found that expanding hematopoietic cell transplant eligibility through mismatched unrelated donors increased racial, ethnic, and socioeconomic diversity among recipients.

Bispecific antibodies show strong efficacy in relapsed/refractory lymphoma and early promise in frontline combination settings.

Data from a large New York State analysis found that sickle cell disease hospitalizations are becoming more severe over time, with significant regional disparities in outcomes, costs, and access to specialized care.

Data from COA highlight operationalizing novel therapies in community cancer care.

Emerging data regarding newly diagnosed AML found that the Endothelial Activation and Stress Index independently predicts early mortality and ICU admission during intensive induction chemotherapy.

COA 2026 reveals how bispecific antibodies transform lymphoma care—outpatient workflows, SOPs, and infection vigilance shape safe BTCE delivery.

Pharmacists play a crucial role in the treatment of patients with chronic myeloid leukemia (CML) taking tyrosine kinase inhibitors.

CAR T drives deep remissions in myeloma and lymphoma, but payers, staffing, and hospital partners shape timely community access.

The cellular FLICE-like inhibitory protein (cFLIP) is a critical regulator of extrinsic apoptosis and essential driver of diffuse large B-cell lymphoma pathogenesis.

EPCORE trial data show epcoritamab plus lenalidomide and rituximab delivers responses in relapsed/refractory follicular lymphoma with outpatient dosing.

Cone Health Cancer Center pharmacists lead bispecific T-cell engager rollout, boosting local access to care.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highlighting novel hematology-oncology options and key pharmacist considerations.

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.

Therapy-related acute myeloid leukemia (tAML) increases as cancer therapy improves, spotlighting AML risk after chemotherapy or radiation and the need for vigilant oncology monitoring.

Phase 3 trial data show that isatuximab quadruplet improves MRD negativity in transplant-eligible patients with multiple myeloma.

Pacritinib bridges high-risk myelofibrosis to allogeneic stem cell transplantation, preserving blood counts, shrinking spleen and symptoms, and enabling 95% of patients to undergo transplantation.

Myelofibrosis model reveals malignant stem cells reprogram healthy support cells, fueling inflammation and fibrosis.